Strikingly, although shRNA knockdown of the individual KDMs did not impinge on the viability of K562 CML cells that harbor wild-type BCR-ABL (Figure 1A), knockdown of KDM6A but not the other KDMs rendered K562 cells more sensitive to apoptosis induced by imatinib (Figure 1B and Figure S1C). This evidence concerns the gene KDM6A and chronic myelogenous leukemia, BCR-ABL1 positive.